McKesson Corporation logo

McKesson Corporation (MCK)

Market Closed
15 Jun, 20:00
NYSE NYSE
$
779. 78
-4.27
-0.5446%
$
94.27B Market Cap
17.39 P/E Ratio
3.28% Div Yield
824,501 Volume
25.95 Eps
$ 784.05
Previous Close
Add Transaction
Day Range
762.54 781.8
Year Range
637 999
Want to track MCK and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
McKesson (MCK) Stock Sinks As Market Gains: Here's Why

McKesson (MCK) Stock Sinks As Market Gains: Here's Why

The latest trading day saw McKesson (MCK) settling at $479.06, representing a -0.02% change from its previous close.

Zacks | 1 year ago
Is Most-Watched Stock McKesson Corporation (MCK) Worth Betting on Now?

Is Most-Watched Stock McKesson Corporation (MCK) Worth Betting on Now?

Zacks.com users have recently been watching McKesson (MCK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks | 1 year ago
Stock Of The Day: Has McKesson Found Its Bottom And Will It Bounce Back?

Stock Of The Day: Has McKesson Found Its Bottom And Will It Bounce Back?

The best traders traders focus on key price levels and stock momentum, understanding that oversold stocks at support often experience a rally.

Benzinga | 1 year ago
McKesson (MCK) Stock Slides as Market Rises: Facts to Know Before You Trade

McKesson (MCK) Stock Slides as Market Rises: Facts to Know Before You Trade

In the latest trading session, McKesson (MCK) closed at $508.16, marking a -0.68% move from the previous day.

Zacks | 1 year ago
Here's Why You Should Retain McKesson Stock in Your Portfolio Now

Here's Why You Should Retain McKesson Stock in Your Portfolio Now

MCK's strategic collaborations and strength in Biologics raise optimism about the stock.

Zacks | 1 year ago
Why McKesson (MCK) is a Top Value Stock for the Long-Term

Why McKesson (MCK) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks | 1 year ago
McKesson - Meet The New Dividend Stock On My Watchlist

McKesson - Meet The New Dividend Stock On My Watchlist

McKesson's recent sell-off offers a compelling opportunity, driven by its strong position in healthcare distribution and growing focus on AI and technology for sustainable growth. The company boasts solid revenue and EPS growth, supported by AI integration, expansion into high-demand sectors like GLP-1 and oncology, and a robust business model. Shareholder returns are enhanced by aggressive buyback plans, a 15% dividend hike, and a healthy balance sheet, despite a low 0.6% dividend yield.

Seekingalpha | 1 year ago
McKesson (MCK) Exceeds Market Returns: Some Facts to Consider

McKesson (MCK) Exceeds Market Returns: Some Facts to Consider

McKesson (MCK) reachead $518.81 at the closing of the latest trading day, reflecting a +1.49% change compared to its last close.

Zacks | 1 year ago
McKesson (MCK) Rises Yet Lags Behind Market: Some Facts Worth Knowing

McKesson (MCK) Rises Yet Lags Behind Market: Some Facts Worth Knowing

McKesson (MCK) concluded the recent trading session at $511.17, signifying a +0.14% move from its prior day's close.

Zacks | 1 year ago
McKesson Corporation (MCK) is Attracting Investor Attention: Here is What You Should Know

McKesson Corporation (MCK) is Attracting Investor Attention: Here is What You Should Know

Zacks.com users have recently been watching McKesson (MCK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks | 1 year ago
McKesson, News Corporation And 2 Other Stocks Executives Are Selling

McKesson, News Corporation And 2 Other Stocks Executives Are Selling

The Nasdaq 100 closed lower by over 500 points during Friday's session. Investors, meanwhile, focused on some notable insider trades.

Benzinga | 1 year ago
McKesson Shares Fall Following Sale of Rexall, Well.ca to Birch Hill

McKesson Shares Fall Following Sale of Rexall, Well.ca to Birch Hill

MCK announces the sale of its Canada-based Rexall and Well.ca businesses to Birch Hill Equity Partners, aligning with its strategy to grow oncology and biopharma services.

Zacks | 1 year ago
Loading...
Load More